Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus chemotherapy or nivolumab plus ipilimumab vs pemetrexed plus platinum in EGFR-mutated T790M-negative NSCLC after EGFR TKI failure
jRCT2080223376Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in EGFR-mutated non-small cell lung cancer (3 arms), sponsored by Bristol Myers Squibb. Started Nov 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080223376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223376.